| Date | Time | Source | | | 02/24/2010 | 4:24PM | MWUS | Bio-Rad Reports Record Fourth-Quarter and Full-Year 2009 Financial Results
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostic products, announced financial results today for the fourth quarter and fiscal year ended December 31, 2009. Fourth-quarter reported revenues were $495.1 million, up 10.5... More...>> |
| 02/04/2010 | 7:45PM | MWUS | Bio-Rad Laboratories, Inc. Announces Completion of Exchange Offer
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostics products, today announced that it has completed its offer to exchange (the "Exchange Offer") up to $300 million aggregate principal amount of its 8.00% Senior Subordinated... More...>> |
| 01/28/2010 | 8:29PM | MWUS | Bio-Rad Laboratories, Inc. Announces Extension of Exchange Offer
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostic products, announced today that its pending offer to exchange (the "Exchange Offer") any and all of its outstanding 8.00% Senior Subordinated Notes due 2016 that were issued... More...>> |
| 01/27/2010 | 7:18PM | MWUS | Bio-Rad to Report Fourth-Quarter and Full-Year 2009 Financial Results Wednesday, February 24, 2010
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostic products, will report financial results for the fourth quarter and full year 2009 on Wednesday, February 24, 2010, after the close of the market. The company will discuss... More...>> |
| 01/13/2010 | 3:38PM | PRNUS | BioInformatics, LLC New Report - The Contract Research Market for Drug Discovery Technologies: Opportunities for Life Science Su
BioInformatics, LLC announces the pending release of its newest report, The Contract Research Market for Drug Discovery Technologies: Opportunities for Life Science Suppliers. As lab budgets remain constricted, pharmaceutical and biotech labs are outsourcing pre-clinical and drug discovery services to create efficiency... More...>> |
| 01/06/2010 | 5:27AM | MWUS | Bio-Rad Completes the Purchase of Certain Diagnostics Businesses of Biotest AG
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostics products, announced today that it has completed the purchase of certain diagnostics businesses of Biotest AG, including its diagnostics products in the areas of blood... More...>> |
| 01/05/2010 | 3:03AM | MWUS | Axis-Shield and Bio-Rad Announce Launch of New Anti-CCP Test for Bio-Rad's BioPlex 2200 System
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostics products, and Axis-Shield plc (LSE: ASD) (OSE: ASD), an international in-vitro diagnostics (IVD) company, today announced the launch of Bio-Rad's BioPlex® 2200 Anti-CCP... More...>> |
| 12/29/2009 | 5:35PM | MWUS | Bio-Rad Laboratories, Inc. Announces Commencement of Exchange Offer of Its 8.00% Senior Subordinated Notes Due 2016 for Register
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostics products, today announced that it has commenced a registered exchange offer to exchange up to $300 million aggregate principal amount of its 8.00% Senior Subordinated... More...>> |
| 11/18/2009 | 3:57PM | PRNUS | Vernier and Bio-Rad to Offer Enhanced Solutions for Biotechnology Education
Vernier Software & Technology, a provider of educational science interfaces, sensors, and software and Bio-Rad Laboratories, Inc., a multinational manufacturer and distributor of life science research and clinical diagnostics products that include its Biotechnology Explorer(TM) program, are combining their respective expertise... More...>> |
| 11/03/2009 | 4:29PM | MWUS | Bio-Rad Reports Third-Quarter Currency-Neutral Revenue Growth of 11 Percent
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostic products, announced financial results today for the third quarter ended September 30, 2009. Third-quarter reported revenues were $461.1 million, up 4.4% compared to $441.8... More...>> |
| 10/23/2009 | 8:28AM | MWUS | Bio-Rad Signs Agreement to Acquire Certain Diagnostics Businesses of Biotest AG
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostics products, announced today that it has signed an agreement to acquire certain diagnostic businesses of Biotest AG for 45 million euros. The terms of the agreement were... More...>> |
| 10/12/2009 | 9:00AM | MWUS | Bio-Rad to Report Third-Quarter 2009 Financial Results Tuesday, November 3, 2009
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostic products, will report financial results for the third quarter 2009 on Tuesday, November 3, 2009, after the close of the market. The company will discuss these results in... More...>> |
| 09/10/2009 | 12:42PM | PRNUS | BioInformatics, LLC New Report - New Media Marketing Channels: Creating Effective Online Life Science Promotional Videos
BioInformatics, LLC (http://www.gene2drug.com/), the premier research and advisory firm serving the life science market, announces the pending release of its newest report, New Media Marketing Channels: Creating Effective Online Life Science Promotional Videos. In this study, nearly 1,300 scientists were surveyed for their... More...>> |
| 08/31/2009 | 9:00AM | MWUS | Bio-Rad Helps Raise $1.1 Million in Napa Valley Tour de Cure
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostics products, helped raise approximately $1.1 million during the Napa Valley Tour de Cure, which took place on May 3 to benefit the American Diabetes Association. As the Presenting... More...>> |
| 08/04/2009 | 4:30PM | MWUS | Bio-Rad Reports Second-Quarter Currency-Neutral Revenue Growth of 3.5 Percent
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostic products, announced financial results today for the second quarter ended June 30, 2009. Second-quarter reported revenues were $427.2 million, down 5.6% compared to $452.4... More...>> |
| 07/20/2009 | 12:05PM | PRNUS | Sysmex America Debuts High-end Sample Management System During AACC
Sysmex America, Inc., a leading medical diagnostic instrument manufacturer and information systems developer, today announced plans to unveil its new Sysmex TS-2000 Tube Sorter during this year's American Association of Clinical Chemistry's (AACC) Annual Conference and Clinical Lab Expo July 19 - 23 in Chicago, Illinois... More...>> |
| 07/13/2009 | 9:00AM | MWUS | Bio-Rad to Report Second-Quarter 2009 Financial Results Tuesday, August 4, 2009
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostic products, will report financial results for the second quarter 2009 on Tuesday, August 4, 2009, after the close of the market. The company will discuss these results in... More...>> |
| 06/01/2009 | 8:30AM | MWUS | Bio-Rad Receives FDA Clearance for ToRC IgG and HSV-1 & HSV-2 IgG Kits on the BioPlex 2200 Multiplex System
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostic products, today announced the FDA clearance of two new multiplex infectious disease serology panels for use on the BioPlex® 2200 system: the BioPlex ToRC IgG panel and... More...>> |
| 05/19/2009 | 6:51PM | MWUS | Bio-Rad Announces Pricing of Private Offering of $300 Million of Senior Subordinated Notes
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostics products, announced that it has agreed to sell $300 million aggregate principal amount of its 8.00% Senior Subordinated Notes due 2016 in a private offering. The Company... More...>> |
| 05/19/2009 | 8:16AM | MWUS | Bio-Rad Announces Private Offering of $250 Million of Senior Subordinated Notes
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostics products, announced today that it intends to commence an offering, subject to market and other conditions, of $250 million aggregate principal amount of senior subordinated... More...>> |
|